Why Repligen Corporation (RGEN) stock moved
Repligen Corporation (RGEN) shares tumbled 5.8% to $136.99 as of July 22, 2026, a significant decline from the prior close of $145.49. BestStocks flagged the session as a major change for RGEN. No single company-specific catalyst was confirmed during the move window. Below, we break down what changed for RGEN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
RGEN fell 5.8% to $136.99
RGEN tumbled 5.8% in its latest session, moving from $145.49 to $136.99.
What it means for Repligen Corporation investors
For Repligen Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Repligen Corporation (RGEN) moved +0.33% from $148.06 to $148.55 on 2026-07-16; Repligen Corporation (RGEN) moved +0.63% from $147.13 to $148.06 on 2026-07-15. Weighing against that: Sharp 5.8% decline — elevated risk; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $152.00, implying +11.0% upside from $136.99. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality weak (0/100). With earnings roughly 6 days out, the next report is the most likely near-term test of the move.
RGEN price reaction
RGEN last traded at $136.99, down $8.50 (-5.84%) from the previous close of $145.49. The session traded on 1.8× average volume (above avg), so the move carried above-average conviction. Over the past month the stock has ranged between $126.37 and $148.55, and it currently sits about 48% of the way up that band.
Bullish and bearish analyst opinions on Repligen Corporation (RGEN)
The consensus analyst price target on Repligen Corporation (RGEN) is $152.00, 11.0% above the recent $136.99. Over the past 90 days analysts logged 1 upgrade, 4 maintains, and 0 downgrades. Here is how the bullish and bearish cases on RGEN line up.
The bullish case
- Wall Street's consensus price target of $152.00 implies +11.0% upside from $136.99.
- The Street's most bullish target is $160.00 (+16.8%).
- 1 analyst upgrade in the past 90 days, most recently Benchmark to Buy (2026-07-07).
- Repligen Corporation (RGEN) moved +0.33% from $148.06 to $148.55 on 2026-07-16.
The bearish case
- Sharp 5.8% decline — elevated risk.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Jul 22, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for RGEN
Frequently asked questions about RGEN
Why did Repligen Corporation (RGEN) stock move?
RGEN tumbled 5.8% to $136.99. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did RGEN stock fall?
RGEN lost 5.84% ($8.50) versus the prior close of $145.49, last trading at $136.99 on 1.8× average volume.
When is Repligen Corporation's next earnings date?
RGEN's next earnings report is estimated for 2026-07-28 — about 6 days away.
What is the analyst price target for RGEN?
The consensus analyst price target for RGEN is $152.00, about 11.0% above the current $136.99. Over the past 90 days, analysts recorded 1 upgrade, 4 maintains, and 0 downgrades.
How BestStocks tracks RGEN
This page is generated automatically by BestStocks' change-detection system after its price and volume cleared RGEN-specific materiality thresholds, triggering an evidence check. It draws on 8 tracked change events for RGEN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of July 22, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.